Key result
SR 121787 is a potent, orally active Gp IIb/IIIa antagonist that strongly inhibits platelet aggregation in vitro and in animal models.
Population
Human platelets (in vitro), baboons, and rabbits (in vivo arterio-venous shunt thrombosis model)
Design
Preclinical
Follow-up
up to 24 hours
Authors
Loading...
Supports development of oral Gp IIb/IIIa antagonists; leaves clinical efficacy and safety untested in humans.
SR 121787 is a potent, orally active Gp IIb/IIIa antagonist with sustained antiaggregating and antithrombotic effects in preclinical models.
Savi et al. (1998) studied this question. SR 121787 was evaluated on Platelet aggregation inhibition and antithrombotic activity. SR 121787 is a potent, orally active Gp IIb/IIIa antagonist that strongly inhibits platelet aggregation in vitro and in animal models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: